GLP-1semaglutideglp-1 receptor agonistsalzheimersmeta-analysis

Meta-analysis finds GLP-1 agonists fail to improve cognition in Alzheimer's

Across seven randomized trials and 4,132 participants, the drugs showed no benefit on ADAS-Cog or CDR-SB but more adverse events.

By Maren Holt · Senior Reporter, GLP-1

Oct 14 20:00 ETSource: Alzheimer's & dementia (New York, N. Y.)

The wire

01Pooled randomized data through April 2026 showed no cognitive benefit (ADAS-Cog SMD -0.05, 95% CI -0.12 to 0.02) and no effect on progression (CDR-SB mean difference 0.09), with adverse events higher (RR 1.07).
02Clinicians fielding patient questions about incretins for dementia prevention now have randomized pooled evidence against a cognitive indication in established disease.
03Biomarker and neuroimaging results were inconsistent; the authors suggest biomarker-enriched, metabolically selected populations or more brain-penetrant agents as the remaining open question.

From the source

GLP-1 receptor agonists in Alzheimer's disease and MCI: a meta-analysis
Alzheimer's & dementia (New York, N. Y.) · 2026 Oct-Dec · Siqueira RGP, Ranalli C, Yılmaz D et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42890838/